Skip to main content
Clinical Trials/NCT00626873
NCT00626873
Completed
Phase 1

Microvascular Perfusion Sonographic Imaging to Detect Early Stage Ovarian Cancer

Icahn School of Medicine at Mount Sinai3 sites in 1 country67 target enrollmentJanuary 2007

Overview

Phase
Phase 1
Intervention
Definity
Conditions
Ovarian Cancer
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
67
Locations
3
Primary Endpoint
Ovarian microvascularity
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

RATIONALE: New diagnostic procedures, such as contrast-enhanced ultrasonography, may be an effective method of finding ovarian cancer.

PURPOSE: This clinical trial is studying how well contrast-enhanced ultrasonography works in diagnosing early-stage ovarian cancer in patients with an adnexal mass undergoing surgery to remove the ovary.

Detailed Description

OBJECTIVES: * Determine whether use of a contrast agent improves the images of the ovaries during ultrasonography. OUTLINE: This is a multicenter study. Patients may undergo baseline transabdominal or transvaginal ultrasonography, if not already done. Patients then undergo contrast-enhanced transabdominal or transvaginal ultrasonography using perflutren lipid microspheres (Definity®) IV. Pathology reports from tissue collected during subsequent oophorectomy is analyzed and compared with ultrasonography findings.

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
February 2012
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Fishman

Professor Obstetrics, Gynecology and Reproductive Science, Director- Gynecologic Oncology Fellowship and National Ovarian Cancer Early Detection Program

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Definity

Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.

Intervention: Definity

Definity

Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.

Intervention: medical chart review

Outcomes

Primary Outcomes

Ovarian microvascularity

Time Frame: 2 years

To evaluate the use of contrast agents to depict the tumor microvascularity to detect ovarian cancer.

Study Sites (3)

Loading locations...

Similar Trials